NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

manibiotech,

First there needs to be a working Flaskworks model in my opinion. I’m sure there are rough draft models but until it is actually up and running with proof of durability and maintenance costs fully explored neither NWBO or NICE will have proof that a model exists that actually is fit for purpose and I believe both parties want that piece fixed before any final agreement.
NWBO is still using the 1,000+ batch number per year for artisan manufacturing capacity and there are no plans to expand artisan so we all can see that demand really can’t be met by artisan manufacturing when considering GBM, rGBM and other demand from just the UK. This is why they have not applied elsewhere. They still need Flaskworks for their own new trials, collaborations with others on new trials or other development and ultimately for broad scale commercial ramp.
With set aside funds in place for payment of treatment during the interim, ramp can go as fast as Advent can handle with artisan and multiple shifts. NICE certainly knows what is coming so what Linda projected over the next 18 months indicates exactly what I am saying. They could have had a model in place by now for artisan and all the details of cost and benefit. Matter of fact NICE probably has a very clear idea of artisan costs and what reimbursement would look like based just on the Specials program so NWBO announcing that they yet need consultants to create a reimbursement model points to everyone waiting on Flaskworks in my opinion. Best wishes.